Cocaine dependence has been linked closely to deficits in the dopamine (DA) brain system. Chronic cocaine users show impairments in cognitive processes known to be regulated by DA (e.g., working memory, decision-making). Consequently, recent medication development efforts have focused on DA-enhancing agents that might """"""""replace"""""""" cocaine and thereby normalize DA-related dysfunction, e.g., levodopa/carbidopa. These agents have shown clinical benefit in reducing cocaine;however there is a substantial subgroup of partial and non-responders for whom levodopa/carbidopa is not sufficient. In addition to DA, cocaine dependence is linked to deficits in serotonin (5-HT) system. Chronic cocaine users show impairments in processes know to be regulated by 5-HT (e.g., impulsivity). Our studies of 5-HT agents, including fluoxetine and citalopram, have shown some benefit in reducing cocaine use, although findings have been mixed across trials and patient subgroups. Since cocaine causes dysfunction in DA and 5-HT systems, an ideal replacement therapy would be expected to target both systems. The proposed study is the first placebo controlled study to examine a dual-deficit model by evaluating the combination of a DA and 5-HT agent for treatment of cocaine dependence. It is hypothesized that the co-administration of levodopa and citalopram will reduce cocaine use and increase periods of sustained abstinence substantially more than either medication alone or placebo. This study will also use novel Bayesian subgroup analyses to evaluate the utility of behavioral laboratory measures as predictors of treatment response. We expect that performance on a battery of neuropsychological tasks (working memory, decision-making, impulsivity) known to be associated with dopaminergic and serotonergic function, will be related to level of response to pharmacological treatment targeting these monoamine systems. Finally, relative changes in performance on these behavioral tasks after three weeks of treatment will be measured as potential mediators of medication response.

Public Health Relevance

This is a phase 2 clinical trial of a new combination pharmacotherapy approach for treatment of cocaine dependence. Co-administration of a dopamine- and serotonin-specific agent is expected to provide greater clinical benefit over single medication treatment. Performance on a set of behavioral tasks will be obtained at baseline and in-treatment to analyze as potential treatment moderators and mediators.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center Houston
United States
Zip Code
D'Souza MA, Johann M; Wardle PhD, Margaret; Green PhD, Charles E et al. (2018) Resting Heart Rate Variability: Exploring Associations With Symptom Severity in Adults With Substance Use Disorders and Posttraumatic Stress. J Dual Diagn :1-6
Vujanovic, Anka A; Wardle, Margaret C; Bakhshaie, Jafar et al. (2018) Distress tolerance: Associations with trauma and substance cue reactivity in low-income, inner-city adults with substance use disorders and posttraumatic stress. Psychol Addict Behav 32:264-276
Miller, William R; Fox, Robert G; Stutz, Sonja J et al. (2018) PPAR? agonism attenuates cocaine cue reactivity. Addict Biol 23:55-68
Vujanovic, Anka A; Smith, Lia J; Green, Charles E et al. (2018) Development of a novel, integrated cognitive-behavioral therapy for co-occurring posttraumatic stress and substance use disorders: A pilot randomized clinical trial. Contemp Clin Trials 65:123-129
Ma, Liangsuo; Steinberg, Joel L; Wang, Qin et al. (2017) A preliminary longitudinal study of white matter alteration in cocaine use disorder subjects. Drug Alcohol Depend 173:39-46
Schmitz, Joy M; Green, Charles E; Hasan, Khader M et al. (2017) PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: a double-blind randomized controlled pilot trial. Addiction 112:1861-1868
Wardle, Margaret C; Vincent, Jessica N; Suchting, Robert et al. (2017) Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder. J Subst Abuse Treat 72:32-39
Ahn, Woo-Young; Ramesh, Divya; Moeller, Frederick Gerard et al. (2016) Utility of Machine-Learning Approaches to Identify Behavioral Markers for Substance Use Disorders: Impulsivity Dimensions as Predictors of Current Cocaine Dependence. Front Psychiatry 7:34
Azadeh, Shabnam; Hobbs, Brian P; Ma, Liangsuo et al. (2016) Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence. Neuroimage 125:813-824
Sharma, Jyoti; Rathnayaka, Nuvan; Green, Charles et al. (2016) Bradycardia as a Marker of Chronic Cocaine Use: A Novel Cardiovascular Finding. Behav Med 42:1-8

Showing the most recent 10 out of 88 publications